One step forward: unique device identification (UDI) system of medicaldevices in EU

Traceability is currently not regulated by MDD 93/42/EEC, nor by IVDD 98/79/EC or AIMD 90/385/EEC. EU Commission published the COMMISSION RECOMMENDATION of 5 April 2013 on a common framework for a unique device identification system of medical devices in the Union.

The Recommendation mainly discusses the Unique Device Identification (UDI) system for the better traceability of medical devices, active implantable medical devices and in-vitro medical devices.

The UDI should comprise two parts, a device identifier and a production identifier, and the system should be implemented gradually, starting from Class III.

Not only manufacturers should keep a close watch to the development and implementation of the UDI system, but importers, EU Authorized Representatives as well as distributors should also be involved.

The implementation date of the UDI System is not clear so far, but this Recommendation is obviously a step forwarder towards the target.

A copy of the recommendation can be downloaded here.

Guidelines on Medical Device Vigilance System Rev 8 released

Revision 8 of MEDDEV 2.12-1, Guidelines on a Medical Device Vigilance System, was released in January 2013, which will be applicable as from July 2013.

This revision's explicitly includes IVF/ART devices within the scope of the vigilance system and provides clarity in relation to devices that are not intended to act directly on the individual.'

A copy of this revision can be downloaded here.

Council Directive 90/385/EEC on Active Implantable Medical Devices

Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices could be downloaded here for reference.

Click to download

EU Commission Press Release: Safer, more effective and innovativemedical devices

EUROPEAN COMMISSION

PRESS RELEASE

Brussels, 26 September 2012

Safer, more effective and innovative medical devices

Ranging from simple sticking plasters to the most sophisticated life-supporting machines, medical devices and in vitro diagnostic medical devices are central to our health and quality of life. To ensure that these devices serve the needs and ensure the safety of European citizens, the European Commission today proposed two Regulations which are fit for purpose, more transparent and better adapted to scientific and technological progress. The new rules aim to ensure that patients, consumers and healthcare professionals can reap the benefits of safe, effective and innovative medical devices. The medical device sector is highly innovative, particularly in Europe and has an estimated market value of around €95bn.

Health and Consumer Policy Commissioner John Dalli said "Just a few months ago, everybody was shocked by the scandal involving fraudulent breast implants which affected tens of thousands of women in Europe and around the world. As policy makers, we must do our best never to let this happen again. This damaged the confidence of patients, consumers and healthcare professionals in the safety of the devices on which they rely every day. The proposals adopted today significantly tighten the controls so as to ensure that only safe devices are placed on the European Union's market at the same time, they foster innovation and contribute to maintaining the competitiveness of the medical device sector."

Who will benefit?

• Patients and consumers since all devices will have to undergo thorough assessment of safety and performance before they can be sold on the European market. Control processes are radically reinforced, but continue to ensure rapid access to innovative, cost-effective devices for European patients and consumers.

• Healthcare professionals will be provided with better information on the benefits for patients, residual risks and the overall risk/benefit ratio, helping them make the best use of medical equipment in their treatment and care of patients.

• Manufacturers will benefit from clearer rules, easier trading between EU countries and a level playing field that excludes those who do not comply with the legislation. The new rules support patient-oriented innovation and take particular account of the specific needs of the many small and medium-sized manufacturers in this sector.

Main elements of the proposals include:

• Wider and clearer scope of EU legislation, extended to include, for example, implants for aesthetic purposes, and clarified for instance, as regards medical software. This will ensure that the safety and performance of these products are correctly assessed before they are placed on the European market;

• Stronger supervision of independent assessment bodies by national authorities;

• More powers and obligations for assessment bodies, to ensure thorough testing and regular checks on manufacturers, including unannounced factory inspections and sample testing;

• Clearer rights and responsibilities for manufacturers, importers and distributors, applying also to diagnostic services and internet sales;

• Extended database on medical devices, providing comprehensive and public        information on products available on the EU market. Patients, healthcare professionals and the public at large will have access to the key data concerning medical devices available in Europe, allowing them to make better informed decisions;

• Better traceability of devices throughout the supply chain, enabling a swift and effective response to safety concerns. A Unique Device Identification system will be introduced to enhance post-market safety of medical devices, to help to reduce medical errors and to fight against counterfeiting;

• Stricter requirements for clinical evidence, to ensure patient and consumer safety;

• Adaptation of the rules to technological and scientific progress, for example the adaptation of the safety and performance requirements applicable to new health technologies, such as software or nano materials used in healthcare;

• Better coordination between national surveillance authorities, to ensure that only safe devices are available on the European market;

• Alignment to international guidelines, to facilitate international trade.

The revised regulatory framework for medical devices is comprised of the following:

• A proposal for a Regulation on medical devices (to replace: Directive 90/385/EEC regarding active implantable medical devices and Directive 93/42/EEC regarding medical devices);

• A proposal for a Regulation on in vitro diagnostic medical devices (to replace Directive 98/79/EC regarding in vitro diagnostic medical devices).

Waste Electrical and Electronic Equipment Directive (WEEE) Affects Medical Devices

In the new Directive 2012/19/EU on waste electrical and electronic equipment approved on 04 July 2012, medical devices are involved in the recovery and recycling scheme as well, whilst the recovery and recycling target tightens in the Directive. Active implantable & infective devices are still excluded.

Time line and recovery/recycling target are summarized as below.

Minimum targets applicable by category from 13 August 2012 until 14 August 2015 with reference to the categories listed in Annex I:

for WEEE falling within category 8 (medical device) of Annex I,

- 70 % shall be recovered, and

- 50 % shall be recycled;

Minimum targets applicable by category from 15 August 2015 until 14 August 2018 with reference to the categories listed in Annex I:

for WEEE falling within category 8 (medical device) of Annex I,

- 75 % shall be recovered, and

- 55 % shall be prepared for re-use and recycled;

Minimum targets applicable by category from 15 August 2018 with reference to the categories listed in Annex III:

for WEEE falling within category 4 (large medical equipment) of Annex III,

- 85 % shall be recovered, and

- 80 % shall be prepared for re-use and recycled;

for WEEE falling within category 5 (small medical equipment) of Annex III,

- 75 % shall be recovered, and

- 55 % shall be prepared for re-use and recycled

EU medical device manufacturers have to implement the Directive, non-EU medical device manufacturers also have to apply through their Authorized Representatives or Distributors, if they tend to market the devices in EU.